Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03866200 · ClinicalTrials.gov registry record · Phase 2
Resveratrol Trial for Relief of Pain in Pseudoachondroplasia
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT03866200 is a Phase 2 study that was terminated before completion, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 6 participants.
The verdict
NCT03866200, a Phase 2 study, was terminated before completion, sponsored by The University of Texas Health Science Center, Houston.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if self-administered oral resveratrol can dampen joint pain for individuals with pseudoachondroplasia compared to placebo. Another goal of this study is to evaluate side effects in this population.
Interventions
- DRUG Placebo
- DRUG resveratrol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-06-29 |
| Est. Completion | 2020-10-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03866200
The ClinicalTrials.gov registry entry for NCT03866200 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03866200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03866200 about?
NCT03866200 is a clinical study titled "Resveratrol Trial for Relief of Pain in Pseudoachondroplasia". The purpose of this study is to determine if self-administered oral resveratrol can dampen joint pain for individuals with pseudoachondroplasia compared to placebo. Another goal of this study is to evaluate side effects in this population.
What is the current status of trial NCT03866200?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2019-06-29. Estimated completion is 2020-10-28.
What interventions are being tested in trial NCT03866200?
The interventions under investigation include: Placebo (DRUG), resveratrol (DRUG).
Who is sponsoring clinical trial NCT03866200?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.